Clinical trial · ClinicalTrials.gov
A Study of Danuglipron in Participants With Type 2 Diabetes
NCT05564117
Trial identity
- Registry
- ClinicalTrials.gov
- Registry ID
- NCT05564117
- Phase
- Phase 2
- Design
- Interventional
- Allocation
- Randomized
- Masking
- Double-blind
- Overall status
- Completed
- Result status
- partial
Sponsors & collaborators
- Sponsor
- Pfizer
- Collaborators
- —
Intervention assets
Arms
| Arm | Intervention | Enrollment |
|---|---|---|
| Danuglipron BID | danuglipron twice daily | — |
| Placebo | placebo twice daily | — |
Population & enrollment
- Population summary
- Adults with type 2 diabetes on stable background therapy.
- Eligibility summary
- HbA1c 7.0-10.5%, BMI ≥25 kg/m².
- Planned enrollment
- 400
- Actual enrollment
- 400
Endpoints
- Primary endpoint
Change in HbA1c from baseline
- Secondary endpoints
Body weight change
Safety and tolerability
Dates
- Start date
- Sep 20, 2022
- Primary completion
- Jun 1, 2024
- Completion date
- Sep 1, 2024
- Last synced
- Aug 15, 2024
Locations
- United States
- Multiple countries
Plain-language interpretation
A Study of Danuglipron in Participants With Type 2 Diabetes is a Phase 2 Interventional sponsored by Pfizer. It is evaluating Danuglipron in Adults with type 2 diabetes on stable background therapy.. The primary endpoint is Change in HbA1c from baseline.
Registry disclaimer: Information is derived from public registry records and may lag behind the official source. Always verify against ClinicalTrials.gov.